Trial Profile
An Extension Trial of Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, for Patients With Advanced Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Ridaforolimus (Primary) ; Ridaforolimus (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Merck & Co; Merck Sharp & Dohme
- 25 Jul 2018 Status changed from active, no longer recruiting to discontinued.
- 25 Jan 2018 Planned End Date changed from 16 Jan 2018 to 9 Jul 2018.
- 25 Jan 2018 Planned primary completion date changed from 16 Jan 2018 to 9 Jul 2018.